Hyong (Nick) Kim, MD

Assistant Professor of Clinical Medicine

CLINICAL INTERESTS:

1. Diagnosis and treatment of Pulmonary Hypertension.
2. Evaluation of pulmonary vascular disorders.
3. Critical Care

INVESTIGATIVE INTERESTS:

1. Pulmonary thromboendarterectomy (PTE) evaluation and outcome.
2. Clinical trials in treatment of pulmonary hypertension.

SELECTED PUBLICATIONS:

1. Kim NH, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J. Cardiovasc. Pharmacol. Ther. 2002; 7:9-19
2. Fedullo PF, Auger WR, Kerr KM, Kim NH. Chronic thromboembolic pulmonary hypertension. Seminars in Resp. and Crit Care Med. 2003; 24: 273-285
3. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of chronic epoprostenol therapy for pulmonary arterial hypertension. Chest 2003 (in press).
4. Kim HS, Fesler P, Channick RN, Naeije R, Rubin LJ. Pre-operative pulmonary artery occlusion measurements correlate with hemodynamic outcome following PTE. Am. J. Respir. Crit Care Med. 2002; 165: A24.
5. Kim NH, Fesler P, Channick RN, Knowlton KU, Ben-Yehuda O, Lee SH, Naeije R, Rubin LJ. Pre-operative partitioning of pulmonary vascular resistance correlates with early outcome following thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Circulation 2004; 109:18-22.
6. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest 2003;124:1612-1615.
7. Fedullo PF, Auger WR, Kerr KM, Kim NH. Chronic thromboembolic pulmonary hypertension. Seminars in Respiratory and Critical Care Medicine 2003; 24:273-285.
8. Kim NH, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther. 2002; 7:9-19.